Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS

Miller, T., Cudkowicz, M., Shaw, P.J. orcid.org/0000-0002-8925-2567 et al. (28 more authors) (2020) Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. New England Journal of Medicine, 383 (2). pp. 109-119. ISSN 0028-4793

Abstract

Metadata

Authors/Creators:
  • Miller, T.
  • Cudkowicz, M.
  • Shaw, P.J. ORCID logo https://orcid.org/0000-0002-8925-2567
  • Andersen, P.M.
  • Atassi, N.
  • Bucelli, R.C.
  • Genge, A.
  • Glass, J.
  • Ladha, S.
  • Ludolph, A.L.
  • Maragakis, N.J.
  • McDermott, C.J. ORCID logo https://orcid.org/0000-0002-1269-9053
  • Pestronk, A.
  • Ravits, J.
  • Salachas, F.
  • Trudell, R.
  • Van Damme, P.
  • Zinman, L.
  • Bennett, C.F.
  • Lane, R.
  • Sandrock, A.
  • Runz, H.
  • Graham, D.
  • Houshyar, H.
  • McCampbell, A.
  • Nestorov, I.
  • Chang, I.
  • McNeill, M.
  • Fanning, L.
  • Fradette, S.
  • Ferguson, T.A.
Copyright, Publisher and Additional Information: © 2020 Massachusetts Medical Society. Reproduced in accordance with the publisher's self-archiving policy.
Dates:
  • Published (online): 9 July 2020
  • Published: 9 July 2020
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 27 Jul 2020 10:20
Last Modified: 09 Jan 2021 01:38
Status: Published
Publisher: Massachusetts Medical Society
Refereed: Yes
Identification Number: https://doi.org/10.1056/nejmoa2003715
Related URLs:

Export

Statistics